Moderna
Open
$49.98
Prev. Close
$50.08
High
$50.05
Low
$49.79
Market Snapshot
$19.71B
-6.2
-9.28
$3.24B
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The company is headquartered in Cambridge, Massachusetts and currently employs 4,700 full-time employees. The company went IPO on 2018-12-07. The company is engaged in developing medicines across infectious disease vaccines, oncology therapeutics and rare disease therapeutics. Its platform incorporates advances across three components, mRNA, delivery, and the manufacturing process, to advance its medicines. Its products are Spikevax and mNEXSPIKE (its COVID vaccines), and mRESVIA (its vaccine against respiratory syncytial virus (RSV)). The company also has a diverse development pipeline that consists of 35 therapeutic and vaccine programs, six of which are in late-stage development. The company has regulatory filings under review for its seasonal flu+COVID vaccine (mRNA-1083) in Europe and Canada and for its seasonal flu vaccine (mRNA-1010) in the United States, Europe, Canada and Australia. Its rare disease programs are Propionic acidemia (mRNA-3927); Methylmalonic acidemia (mRNA-3705), and Cystic Fibrosis (mRNA-3692/VX-522).
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The company is headquartered in Cambridge, Massachusetts and currently employs 4,700 full-time employees. The company went IPO on 2018-12-07. The company is engaged in developing medicines across infectious disease vaccines, oncology therapeutics and rare disease therapeutics. Its platform incorporates advances across three components, mRNA, delivery, and the manufacturing process, to advance its medicines. Its products are Spikevax and mNEXSPIKE (its COVID vaccines), and mRESVIA (its vaccine against respiratory syncytial virus (RSV)). The company also has a diverse development pipeline that consists of 35 therapeutic and vaccine programs, six of which are in late-stage development. The company has regulatory filings under review for its seasonal flu+COVID vaccine (mRNA-1083) in Europe and Canada and for its seasonal flu vaccine (mRNA-1010) in the United States, Europe, Canada and Australia. Its rare disease programs are Propionic acidemia (mRNA-3927); Methylmalonic acidemia (mRNA-3705), and Cystic Fibrosis (mRNA-3692/VX-522).
Recently from Cashu
Moderna Stock Drops 8% Amid FDA Leadership Change and Vaccine Approval Uncertainty
Moderna Faces Uncertainty Following Regulatory Leadership Change Moderna, a leading biotechnology firm, experiences heightened scrutiny following the resignation of Peter Marks, the FDA's prominent va…
Moderna Faces Uncertainty as FDA Vaccine Regulator Resigns Amid Public Health Controversies
FDA Shake-Up Poses Challenges for Vaccine Manufacturers The recent resignation of Peter Marks, the FDA's leading vaccine regulator, sends shockwaves through the biotech sector, particularly impacting…
Moderna Faces Uncertainty After FDA Regulator Resignation Amid Vaccine Oversight Concerns
Regulatory Shift Raises Concerns for Vaccine Innovators The resignation of Peter Marks, the FDA's top vaccine regulator, sends shockwaves through the biotech industry, particularly affecting companies…
Moderna Faces Major Challenges Amidst Market Volatility and Economic Uncertainty
Moderna Faces Significant Challenges Amid Market Volatility In the current financial landscape, the biotechnology sector, particularly companies like Moderna, grapples with substantial hurdles that ex…